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Abstract
Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics
can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for
mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between
genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a
panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite
signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the
total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and
Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR
were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass
index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the
magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and
intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several
secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a
single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These
findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease,
indicate that interactions between genome, gut microbiome and environmental influences should be considered in the
study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment
outcomes and could contribute to a more personalized approach to therapy.
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Introduction
Statins are HMG-CoA reductase inhibitors that are widely used
to reduce plasma levels of LDL cholesterol (LDL-C) and the risk
for coronary artery disease (CAD) [1,2,3,4]. However, statins also
have a number of other important biological actions that may
contribute to treatment benefit (e.g,, reducing inflammation) or
adverse events, (e.g., myopathy, increased risk for type 2 diabetes
mellitus [5]. Furthermore, efficacy of statins for lowering LDL-C
and for reducing CAD risk can vary greatly among individuals [6].
For these reasons, identification of pre-treatment metabolic
signatures or ‘‘biomarkers’’ predictive of response would be useful
for targeting this drug to the population that may benefit most
from its use.
Metabolomics brings powerful tools for mapping the metabolic
state of individuals prior to treatment and global biochemical
changes induced by drug treatment [7,8,9,10]. Recently we
reported that baseline metabolic profiles so called metabotypes do
inform about trajectory of response to antidepressants escitalo-
pram and sertraline [7,8]. A new field is evolving called
Pharmacometabolomics (also pharmacometabonomics) for appli-
cations of metabolomics in personalized medicine [10] and where
biochemical data is being used to inform about treatment
outcomes.
While it is well established that response to therapeutics can be
affected by genetic and environmental factors, the enteric
microbiome might also play a role in uncharacterized ways.
Metabolomics provides a unique method to characterize the net
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by members of this group and others, have identified genetic
polymorphisms that contribute to variability in the LDL-C
response to statins [6], but only a small proportion of the variance
has been explained by these factors [11]. Some statins are
administered as inactive precursor drugs that are activated by
endogenous biotransformation pathways, and there is increasing
interest in the role of gut bacteria in the metabolism of drugs [12]
including simvastatin. Metabolomics can capture a unique portrait
of the state and changes of the gut microbiota by direct
measurements of metabolite production [12,13,14]. Recently
several metabolites produced by the gut microbiome were
implicated in cardiovascular disease [15], highlighting for the first
time an important and complementary role that the gut
microbiome plays in cardiovascular health, and indicating the
need to study net interactions between genome, gut microbiome
and the environment.
Given that the primary cellular action of statins is well upstream
of the factors that modulate plasma lipoprotein metabolism, there
are many potential pathways that may act to influence the
magnitude of the statin response. In this study, we sought to
identify metabolites whose plasma levels predict LDL-C lowering
response to statin treatment (simvastatin 40 mg/day) using a
defined metabolomic approach. We measured a targeted panel of
metabolites related to cholesterol metabolism in three known
pathways: cholesterol synthesis, dietary sterol absorption, and bile
acid formation. We detected significant correlations between gut-
derived metabolites and simvastatin response. This supports
further evidence that the genome, the microbiome and diet all
contribute to mechanisms of variation of response to simvastatin.
Results
Pre-treatment levels of metabolites correlated with
LDL-C reduction
Two subgroups of subjects were selected from the 944
participants in the Cholesterol and Pharmacogenetics (CAP)
study: 1) 100 individuals randomly selected from and representa-
tive of the entire range of LDL-C response, defined as the
percentage change in LDL cholesterol from pretreatment levels
(full range, FR); and 2) 24 individuals each selected from the top
and bottom 10% tails of the LDL-C response distribution
(total=48) with matching of individuals from the two tails for
body mass index, race, and gender (Table 1). There was a slightly
lower proportion of men in the GPR than in the FR groups, but
the two groups were similar in age, race, BMI, initial LDL-C,
initial HDL-C, and initial total cholesterol. The two groups cannot
be differentiated using these pretreatment measures.
A. Analysis of Full Range (FR) Samples
Using a targeted metabolomics platform with which we
evaluated 12 sterols and 14 bile acids, we observed in the
randomly selected (FR) subjects a very strong correlation between
a lower pretreatment level of several endogenous primary and
secondary bile acids—taurocholic acid (TCA), glycocholic acid
(GCA), taurochenodeoxycholic acid (TCDCA), glycochenodeoxy-
cholic acid, (GCDCA) and glycoursodeoxycholic acid (GUDCA)
—and greater response to the LDL lowering effects of simvastatin
(Fig. 1 and Table 2). Bile acids were the only compounds for which
we observed a significant correlation with LDL reductions in this
random sample from the full range of subjects.
A correlation matrix shows all correlations between the FR
pretreatment metabolites and LDL-C response (Fig. 2). All of the
metabolites within the cholesterol biosynthetic pathway except
cholestanol (CSTN) were positively correlated with each other but
they were not strongly correlated with LDL-C response. The
dietary sterols, b-sitosterol (b-SITO), stigmasterol (STIG), and
campesterol (CAMP) were highly positively correlated with each
other, and were negatively correlated with most cholesterol
biosynthesis metabolites, and bile acids. Coprostanol (COPR)
did not correlate with the other dietary sterols and was negatively
correlated with LDL-C response to statins, while b-SITO, STIG
and CAMP were slightly positively correlated with LDL-C
response. Most bile acids were positively correlated with each
other. The primary bile acids cholic acid (CA) and chenodeoxy-
cholic acid (CDCA) were positively correlated with most other bile
acids except the secondary bile acids lithocholic acid (LCA),
taurolithocholic acid (TLCA), and glycolithocholic acid (GLCA).
A set of primary and secondary bile acids was positively and
significantly correlated with LDL-C.
B. Analysis of Good/Poor Responders (GPR)
We next evaluated samples from the tails of the spectrum of
LDL-C response, that is, subsets of the best and worst responders
to simvastatin therapy (Fig. 3). As shown in Figure 3 and Table 3,
we observed a strong relationship between the level of reduction in
LDL-C levels and higher pretreatment levels of the secondary bile
Table 1. Demographics of patients included in metabolomics study.
GPR FR
Subjects selected from: Good Responders Poor Responders Full Range Subjects
Total, n 24 24 100
Male, % 33 33 48
Body Mass Index kg/m
2 28.566.4 29.165.1 28.565.1
Race % African American 25 29 30
Decrease in LDL-C, % 63.0664.2 7.6269.4 41.4+11.7
Age, y 60.3613.8 53.1612.4 53.6+12.6
Initial LDL-C, mg/dL 133.2631.9 120.1629.6 138.4635.5
Initial HDL-C, mg/dL 58.17615.46 53.66618.57 52.6616.5
Initial Total Cholesterol, mg/dL 219.58639.55 201.75632.71 215.8639.2
Values are mean 6 SD.
doi:10.1371/journal.pone.0025482.t001
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produced in the intestine by enteric bacterial reduction of
endogenous cholesterol.
Separate correlation matrices for the good and the poor
responders show all correlations of pretreatment metabolites
within each group (Fig. 4). There were some strong positive
correlations within the cholesterol biosynthesis metabolites, dietary
sterols, and bile acids in both good and poor responders. COPR
had a positive correlation with the dietary sterols in the good
responders and no correlation in the poor responder subjects. Bile
acids were also different between the good and poor responders,
with primary bile acids (TCA, GCA, TCDCA, GCDCA) changing
from no correlation with cholesterol biosynthesis and negative
correlation with dietary sterol metabolites in good responders to a
slightly positive correlation in poor responders. Conversely,
secondary bile acids (deoxycholic acid DCA, taurodeoxycholic acid
Figure 1. Sterol pathway map testing the association of pretreatment metabolites with change of LDL-C by statin treatment. The
map was constructed using a correlation of pretreatment metabolites with change in LDL-C in FR. The color scheme corresponds to correlation
strength as shown by the color bar. Red: Better response, more reduction of the metabolite. Blue: Better response, less reduction or increase of the
metabolite. Correlations to change in LDL-C are given in the first row and column. The metabolites are rescaled (divided by the largest absolute value
of them) to be clearer in the map. * Correlations significant by p-value, but not significant after controlling for q-value. ** Correlations significant by
p-value and significant after controlling for q-value.
doi:10.1371/journal.pone.0025482.g001
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correlation with cholesterol biosynthesis metabolites in good
responders and a negative correlation in the poor responders.
Pre-treatment levels of metabolites correlated with
on-treatment simvastatin concentration
Pretreatment concentrations of two bile acids, CDCA and DCA,
were positively correlated with on-treatment plasma simvastatin
acid concentrations in the FR subjects (Table 4). Neither pre- nor
post-treatment level of LDL-C was significantly correlated with
plasmasimvastatinconcentrationinthisstudy (Table 4 and data not
shown) or in the entire CAP study (data not shown).
Several bile acids were correlated with simvastatin acid
concentrations inthegood andthepoorresponders, with borderline
significant q-values (Table 4). These include negative correlations to
CDCA and positive correlations toLCAingood responders;and, in
poor responders, negative correlations to both secondary bile acids
(DCA and LCA) that were positively correlated to simvastatin acid
levels in good and normal range responders.
Pre-treatment levels of several metabolites correlated
with SLCO1B1 gene polymorphisms
We tested the FR subjects for associations of plasma lipid
metabolites with SNP rs4149056 in the gene encoding the organic
anion transporter SLCO1B1. In the full CAP study population,
this SNP was strongly associated with fasting simvastatin acid
concentration (p,0.0001, r=0.23, R. Krauss, personal commu-
nication), consistent with earlier observations [16]. We were
interested in determining whether SNP rs4149056 was associated
with levels of sterol/bile acid metabolites whose pre-treatment
concentrations had been correlated with simvastatin LDL
response. Our analysis (Table 5) revealed that seven bile acids
showed nominally significant associations with this SNP, such that
the minor allele was associated with higher plasma levels. These
include two secondary bile acids, LCA and TLCA, which we
identified as markers for greater response to simvastatin lowering
of LDL-C levels in good responders. LDL-C reduction in FR
subjects was also correlated with post simvastatin treatment levels
of LCA and TLCA (data not shown). The minor allele of
rs4149056 was also associated with increased plasma levels of 7a-
hydroxycholesterol, the product of the rate-limiting step in
synthesis of bile acids from cholesterol (Table 5).
We also analyzed a second SLCO1B1 SNP (rs2306283, an
N130D coding variant) that was not associated with plasma
simvastatin acid levels and found a significant correlation only with
plasma stigmasterol concentration (Table 6).
Discussion
Statins lower plasma LDL-C by blocking the activity of HMG-
CoA reductase, thereby decreasing the synthesis of cholesterol
and modifying downstream metabolic pathways. In our previous
study we evaluated over 300 lipid species within eight lipid classes
and found that baseline cholesterol ester and phospholipid
metabolites correlated with LDL-C response to treatment [17].
This study builds on our previous work to investigate sterol
metabolism in more depth and beyond effects on HMG-CoA
reductase. We used a selective analytic platform to assay levels of
sterol metabolites in plasma of participants in a trial of
simvastatin treatment in order to identify biomarkers that
correlate with statin lipid-modifying efficacy. We investigated
metabolite levels from both the best and worst responders as well
as from subjects with a full range of response. Doing so allowed us
to explore and verify the effects of statin treatment in two
population subsets representing a wide range of LDL-C
responses. The FR subset provided an assessment of the
predictors of statin response that is applicable to a wide range
of statin-treated patients. On the other hand, the GPR subset
provided a means to explore the differences in metabolite
predictors of the highest and lowest responses to drug therapy,
although the results may be applicable to only a small subset of
patients who take simvastatin. We identified a positive correlation
between LDL-C response and specific primary and secondary
bile metabolites including TCA, GCA, TCDCA, GCDCA and
GUDCA. In addition, there was a negative correlation in the
GPR group with secondary bile acids produced by intestinal
bacteria. These enteric bacterially produced bile acids included
lithocholic acid (LCA) and the conjugated derivatives glycolitho-
cholic acid (GLCA) and taurolithocholic acid (TLCA). The
observation that different secondary bile acids were inversely
associated with LDL-C response in the two study subsets may
signify differing specific relationships among extreme responders
compared with the remainder of the population.
In this study there were no strong correlations between
pretreatment bile acid metabolites and HDL-C response to
simvastatin (data not shown), which further supports the specificity
of the relationship between the concentration of the bile acid
metabolites and LDL-C response.
Table 2. Pretreatment metabolites that correlate with change
of LDL-C in FR group.
Association with LDL-C change
Metabolic Pathway Metabolite Correlation P value Q value
Sterol Synthesis LANO negative 0.8947 0.6770
LATH negative 0.7464 0.6212
7.DHC negative 0.9341 0.6770
DESM positive 0.6398 0.5749
CHOL positive 0.3984 0.4475
CSTN negative 0.5886 0.5696
7.HC positive 0.0266 0.0683
Dietary Sterols COPR negative 0.1692 0.3041
B.SITO positive 0.3330 0.4275
STIG positive 0.1084 0.2165
CAMP positive 0.4435 0.4688
Primary Bile Acids CA negative 0.9417 0.6770
CDCA positive 0.2342 0.3238
TCA positive 0.0023 0.0207
GCA positive 0.0038 0.0228
TCDCA positive 0.0011 0.0198
GCDCA positive 0.0120 0.0359
Secondary Bile Acids DCA positive 0.7604 0.6212
TDCA positive 0.0110 0.0359
GDCA positive 0.0607 0.1364
LCA positive 0.3651 0.4374
TLCA positive 0.2007 0.3088
GLCA positive 0.6022 0.5696
UDCA positive 0.2062 0.3088
GUDCA positive 0.0097 0.0359
doi:10.1371/journal.pone.0025482.t002
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nutrient molecules including cholesterol, and other endogenous
and exogenous sterols. Accordingly, the complex interplay of
endogenous primary and bacterial metabolized secondary bile
acids can affect the retention and metabolism of plasma
cholesterol. Bile acids are known to be important endocrine
signals, functioning in the systemic control of lipid levels, muscle
function and immune cell regulation [18]. It has not escaped our
attention that all of these pathways are affected by statins, either as
therapeutic target or side effects, suggesting that bile acids may be
important mediators of statin activities.
In addition to secondary bile acids, we observed a correlation
between response to simvastatin and higher pre-treatment levels of
coprostanol (COPR) (Figs. 1, 2, and 3). This compound is used as
an environmental marker for the presence of human fecal matter
and is produced by intestinal bacteria by hydroxylation of
cholesterol (Fig. 5). The cholesterol to coprostanol ratio has been
used as a measure of ability to remove cholesterol from circulation,
and has been shown to be controlled by the amount of
coprostanoligenic bacteria in the gut [19]. Specific strains of
Lactobacillae bacteria isolated from fermented dairy products have
been characterized by their ability to convert cholesterol to
coprostanol and have been suggested as probiotic alternatives for
reducing cholesterol levels [20]. Our data suggest that patients
with higher pretreatment levels of coprostanoligenic bacteria will
respond more robustly to the LDL-C lowering effects of
simvastatin. Other investigators have linked enteric bacteria
metabolism with cardiovascular changes and disease outcome in
animal models using metabolomics [15]. The work presented here
expands that concept and provides a link between enteric bacterial
metabolism and therapeutic outcome of simvastatin treatment in
humans.
Another potential basis for the relationship between gut
microbial metabolism and statin efficacy is an effect on drug
absorption or other factors affecting drug pharmacokinetics [12]
or drug pharmacodynamics.
Our analyses identified primary and secondary bile acids for
which pretreatment concentrations were correlated with on-
treatment plasma simvastatin acid levels. Primary bile acids (CA
and CDCA) and simvastatin are all metabolized by the P450
enzyme CYP3A4 [21,22]. Simvastatin is transported by multidrug
resistance gene 1 (MDR1, ABCB1) P-glycoprotein, multidrug
resistance-associated protein 2 (MRP2, ABCC2), and organic
anion-transporting polypeptide 1B1 [23,24]. Polymorphisms in
these proteins are known to influence simvastatin pharmacokinet-
ics [25,26,27]. These transporters are also responsible for the
transport of bile acids in the gastrointestinal tract and liver [28,29].
At the same time simvastatin and bile acids also regulate the
expression of these transporters [28,30,31,32]. Interactions
between simvastatin and selected bile acids competing for
membrane transport may be responsible for some of the off target
effects of the drug [33].
We speculate that the correlations between plasma simvastatin
and bile acids occurred because transport of these compounds to
or from the plasma is limiting. Therefore genetic polymorphisms
which alter the activity or amount of hepatic transporters could
Figure 2. Correlation matrix for testing the association of pretreatment metabolites with a change in LDL-C by statin treatment. The
correlationmap shows pretreatment metabolites andchangeinLDL-C inFR. Thecolorscheme correspondstocorrelationstrength asshownbythecolor
bar.Red:Betterresponse, morereduction ofthe metabolite.Blue: Better response, lessreductionorincreaseofthemetabolite.Correlations tochangesin
LDL-Caregiven inthefirst rowandcolumn. The metabolites havebeenrescaled(dividedbythe largest absolute value ofthem) tobeclearer onthe map.
doi:10.1371/journal.pone.0025482.g002
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Genetic analyses of the CAP population, including the subjects in
this study, have identified correlations between a SLCO1B1 SNP
and plasma levels of simvastatin acid as well as specific primary
and secondary bile acids. The SLCO1B1 transporter is of
particular interest because it is known to transport simvastatin
from plasma into the liver, and SNP rs4149056 has been
associated with statin-induced myopathy in individuals treated
with high dose simvastatin [34]. The present results are generally
consistent with those published recently from a much smaller study
population [16] and demonstrate that SLCO1B1 plays an
important role in hepatic uptake of bile acids as well as
simvastatin. Further, they raise the possibility that competition
between simvastatin and bile acids for this transporter may
Figure 3. Sterol pathway map testing the association of pretreatment metabolites with changes in LDL-C from statin treatment. The
map has been constructed using the correlation of pretreatment metabolites with change of LDL-C in GPR. Enzymes are represented by circles;
metabolites by squares. Metabolites in grey squares were not quantified. White squares were not significantly different. The metabolites with
significant p-values are colored according to the correlation relationship with blue negative and red positive. Red: Better response, more reduction of
the metabolite. Blue: Better response, less reduction or increase of the metabolite. Correlations to changes in LDL-C are given in the first row and
column. The metabolites have been rescaled (divided by the largest absolute value of them) to be clearer on the map. * Correlations significant by
p-value, but not significant after controlling for q-value. ** Correlations significant by p-value and significant after controlling for q-value.
doi:10.1371/journal.pone.0025482.g003
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simvastatin, and possibly risk of muscle toxicity. It should be
pointed out however that the findings from the present study may
not be applicable to other statins, whose interactions with bile acid
metabolism and transport may differ from those of simvastatin.
The present findings point to the utility of metabolomic surveys
for identifying predictors of clinical response that may have
implications for assessing efficacy of this widely-used class of drugs.
We have observed that the pretreatment levels of bile acids derived
from gut bacteria and nutrient inputs are correlated with response
to simvastatin. It is becoming increasingly clear that gut microbial
symbiots are critical for normal digestion and defense, and also
play an important role in development of disease [15] and in
metabolizing orally ingested therapeutics [12]. There is increasing
recognition that intestinal bacteria can metabolize drugs and alter
an individual’s response to drug treatment depending on specific
bacterial strains present [35]. In an interesting corollary to our
work, Ridlon et al. have suggested that probiotics, by altering
intestinal microflora, can alter the enterohepatic circulation of
secondary bile acids [36]. In addition, Wang et al. recently have
implicated enteric bacteria and phosphatidylcholine metabolism in
the pathogenesis of cardiovascular disease [15]. We suggest that
our findings warrant further evaluation of interactions of specific
markers for gut microbiota and therapeutic response to statins.
Identification of the basis for such interactions may in turn lead to
dietary or other interventions that can improve statin efficacy by
altering gut microflora.
Methods
Subjects
Plasma samples were analyzed from participants in the
Cholesterol and Pharmacogenetics (CAP) study—a trial in which
944 Caucasian and African-American men and women with total
cholesterol levels of 160–400 mg/dL were treated with simvastatin
40 mg/d for 6 weeks. This study was designed to examine genetic
and non-genetic factors affecting the response to simvastatin
therapy in healthy, drug-naı ¨ve patients [37]. Participants were
Table 3. Pretreatment metabolites correlated with treatment
outcomes in patients selected from the ends (comparing
good and poor responders).
Metabolic Pathway Metabolite Correlation P value Q value
Sterol Synthesis LANO positive 0.9037 0.9596
LATH negative 0.4350 0.7932
7.DHC negative 0.3388 0.7932
DESM negative 0.1498 0.4680
CHOL negative 0.1170 0.4179
CSTN positive 0.8517 0.9596
7.HC negative 0.8345 0.9596
Dietary Sterols B.SITO negative 0.9212 0.9596
CAMP positive 0.7004 0.9596
COPR negative 0.0242 0.2016
STIG positive 0.3851 0.7932
Primary Bile Acids CA positive 0.4126 0.7932
CDCA positive 0.0991 0.4129
TCA negative 0.4628 0.7932
GCA negative 0.8398 0.9596
TCDCA negative 0.7576 0.9596
GCDCA negative 0.7739 0.9596
Secondary Bile Acids DCA negative 0.6938 0.9596
UDCA negative 0.9915 0.9915
LCA negative 0.0443 0.2770
TDCA negative 0.0568 0.2841
GDCA negative 0.2376 0.6599
GUDCA negative 0.4759 0.7932
TLCA negative 0.0198 0.2016
GLCA negative 0.0234 0.2016
doi:10.1371/journal.pone.0025482.t003
Figure 4. Correlation matrices of pretreatment sterol metabolites in good and poor responders. The differences between the two
matrices reflects the differences between the groups responses to statin treatment. The color scheme corresponds to correlation strength as shown
by the color bar. Red: Better response, more reduction of the metabolite. Blue: Better response, less reduction or increase of the metabolite. The
metabolites have been rescaled (divided by the largest absolute value of them) to be clearer on the map.
doi:10.1371/journal.pone.0025482.g004
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bedtime) and were seen at clinic visits conducted at 2-week
intervals. Blood specimens from each subject were obtained after
overnight fast at the screening visit, after a 2-week placebo run-in
(enrollment visit), and following 4 and 6 weeks of simvastatin
administration. Samples used in this study were collected pretreat-
ment and at 6 weeks of therapy. Simvastatin concentrations were
analyzed in the samples collected at 6 weeks. Compliance was
assessed by pill count every 2 weeks and averaged more than 95%.
Overall, treatment with simvastatin lowered LDL-C by 54 mg/dl
and increased HDL cholesterol (HDL-C) by 2 mg/dl. The
magnitude of the lipid and lipoprotein responses, however, differed
among participants according to a number of phenotypic and
demographic characteristics [37]. Data on dietary intake was not
collected, but subjects were instructed not to change their diet. IRB
approval was granted by the participating institutions and informed
consent was obtained from all participants in CAP.
Two subgroups of subjects were selected for study. The first
(good/poor responders, GPR) consisted of 24 individuals selected
from the top 10% of the LDL-C response distribution who were
matched for body mass index (BMI), race, and gender to 24
individuals in the lowest 10% of responders, with response to
therapy defined as the percentage change in LDL cholesterol from
pretreatment levels. A second set of 100 individuals (full range, FR)
was randomly selected from the entire CAP study, excluding
subjects who had been selected for the initial GPR group. These
subjects are representative of the population for age, race, gender,
and BMI. Metabolomic analyses of statin-induced changes in the
fatty acid content of the major lipid classes in the FR group have
been reported recently [17].
Table 4. Pretreatment sterol metabolites and bile acids
correlated with simvastatin concentrations.
Metabolite Correlation P value Q value
Full Range CDCA 0.21 0.039 0.09
DCA 0.24 0.019 0.09
LDL-C 0.038 0.71 0.21
Good Responders CDCA 20.47 0.035 0.2
LCA 0.47 0.033 0.2
Poor Responders LANO 0.44 0.034 0.2
TCA 0.49 0.017 0.17
TCDCA 0.42 0.043 0.21
DCA 20.54 0.0078 0.17
LCA 20.5 0.014 0.17
doi:10.1371/journal.pone.0025482.t004
Table 5. Association of SLCO1B1 SNP rs4149056 with
pretreatment measurements for sterols and bile acids in CAP
participants.
Metabolites Estimate P value Q value
LANO 0.15 0.13 0.18
LATH 0.11 0.29 0.28
7.DHC 0.13 0.2 0.24
DESM 0.071 0.48 0.37
CHOL 0.15 0.14 0.18
CSTN 0.017 0.87 0.53
7.HC 0.21 0.039 0.088
COPR 0.085 0.4 0.34
B.SITO 0.0038 0.97 0.55
STIG 20.12 0.23 0.25
CAMP 20.057 0.57 0.37
CA 0.22 0.026 0.088
CDCA 0.11 0.26 0.27
TCA 0.22 0.03 0.088
GCA 0.26 0.0084 0.088
TCDCA 0.23 0.023 0.088
GCDCA 0.16 0.12 0.18
DCA 0.064 0.53 0.37
TDCA 0.16 0.12 0.18
GDCA 0.17 0.088 0.17
LCA 0.21 0.04 0.088
TLCA 0.22 0.027 0.088
GLCA 0.065 0.52 0.37
UDCA 0.056 0.58 0.37
GUDCA 0.087 0.39 0.34
doi:10.1371/journal.pone.0025482.t005
Table 6. Association of SLCO1B1 SNP rs2306283 with
pretreatment measurements of sterols and bile acids in CAP
participants.
Metabolites Estimate P value Q value
LANO 20.11 0.29 0.6
LATH 20.02 0.84 0.6
7.DHC 20.027 0.79 0.6
DESM 0.046 0.65 0.6
CHOL 20.15 0.15 0.6
CSTN 20.049 0.63 0.6
7.HC 20.08 0.43 0.6
COPR 20.076 0.46 0.6
B.SITO 20.17 0.09 0.58
STIG 20.28 0.0045 0.086
CAMP 20.19 0.064 0.58
CA 20.038 0.71 0.6
CDCA 20.058 0.57 0.6
TCA 20.042 0.68 0.6
GCA 20.077 0.45 0.6
TCDCA 20.043 0.68 0.6
GCDCA 20.039 0.7 0.6
DCA 20.031 0.76 0.6
TDCA 0.018 0.86 0.6
GDCA 20.017 0.87 0.6
LCA 20.056 0.59 0.6
TLCA 0.015 0.89 0.6
GLCA 20.027 0.79 0.6
UDCA 0.08 0.43 0.6
GUDCA 0.019 0.85 0.6
doi:10.1371/journal.pone.0025482.t006
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significantly older than poor responders, with marginally higher
initial cholesterol, HDL-C, apolipoprotein AI (apoAI), and
apolipoprotein B (apoB) levels The FR group, with the broad
response range, had a slightly higher percentage of men than Group
1, but was matched for race, age, and initial cholesterol levels.
Laboratory measurements
Plasma LDL-C, HDL-C, apoAI and apoB were measured as
described previously (Simon et al., 2006). Lipid extraction, solid-
phase extraction, and capillary gas-liquid chromatography were
used for quantitative analysis of sterols according to the method of
Phillips et al. [38]. The analysis was conducted using an Agilent
5975 GC/MSD. Bile acids were extracted using a sample
preparation involving protein precipitation as described in
Tagliacozzi et al. [39]. Analysis separations were performed by
the Agilent 1200 RRLC (rapid resolution liquid chromatograph)
using a Zorbax 1.8 micron column; bile acids were detected with
the 4000 Qtrap (Applied Biosystems) by monitoring the analytes
under multiple reaction-monitoring mode as described in Burkard
et al. [40]. The following sterols and bile acids were detected and
quantified: campesterol (CAMP), chenodeoxycholic acid (CDCA),
cholestanol (CSTN), 4-cholesten-7a-ol-3-one (4-CHST), choles-
terol, cholic acid (CA), coprostanol (COPR), 7-dehydrocholesterol
(7-DCH), deoxycholic acid (DCA), desmosterol (DESM), glyco-
chenodeoxycholic acid (GCDCA), glycocholic acid (GCA),
glycodeoxycholic acid (GDCA), glycolithocholic acid (GLCA),
glycoursodeoxycholic acid (GUDCA), 7a-hydroxycholesterol (7a-
HC), lanosterol (LANO), lathosterol (LATH), lithocholic acid
(LCA), b-sitosterol (b-SITO), stigmasterol (STIG), taurocheno-
deoxycholic acid (TCDCA), taurocholic acid (TCA), taurodeoxy-
cholic acid (TDCA), taurolithocholic acid (TLCA), and ursodeoxy-
cholic acid (UDCA).
The levels of activated metabolite of simvastatin, simvastatin
acid, were determined by mass spectrometry as described
elsewhere [41]. Analysis of the SLCO1B1 rs4149056 single
nucleotide polymorphism (SNP) was performed by BeadArray
technology (Illumina, San Diego, CA).
Statistical analyses
We tested the correlation of pretreatment metabolites with drug
response. Metabolites were log-transformed before correlation
testing. For FR subjects, Spearman’s correlation coefficient was
used to obtain correlation coefficients between the pretreatment
level of each metabolite with changes in LDL-C or HDL-C.
Because changes in LDL-C and HDL-C are correlated with
pretreatment LDL-C and HDL-C concentrations, respectively, the
changes ofthese measurements were adjusted fortheir pretreatment
levels \. Correlations among pretreatment metabolites were
obtained by deriving Spearman’s correlation coefficient between
each pair. For GPR subjects, Wilcoxon rank sum tests were used to
test differences in pretreatment metabolites between good respond-
ers and poor responders. Correlation maps were constructed using
the algorithm in Ayroles et al. [42]. The degree of correlation
between each two metabolites was color-coded. Metabolites were
listed in the order of the pathway maps for sterol metabolism.
Figure 5. Active cholesterol metabolites are produced by interspecies biosynthetic pathways. Bile acids are the main metabolites of
cholesterol (CHOL). Primary bile acids (blue ovals; cholic acid (CA) and chenodeoxycholic acid (CDCA)) are produced by endogenous enzymes in the
liver and are modified by bacteria of the genus Clostridia colonizing the gut to form secondary bile acids (yellow ovals; lithocholic acid (LCA) and
deoxycholic acid [18]). Arrows broken by double lines represent multiple enzymatic steps and only the genes encoding the rate limiting enzymes are
listed. The bacterial operon baiABCDEFGHI encodes eight enzymes and a bile acid transporter that together form the pathway for synthesis of
secondary bile acids. The amino acids glycine and taurine are conjugated to primary and secondary bile acids in the liver by the host encoded bile
acid-CoA amino acid transferase (BAAT) to form tauro- and glycolithocholic acid (TLCA, GLCA) and tauro- and glycodeoxycholic acid (TDCA GDCA).
Gut bacteria of genus Lactobacillus catalyze the conversion of cholesterol metabolites to coprostanol (COPR) and can limit the intestinal absorption of
cholesterol.
doi:10.1371/journal.pone.0025482.g005
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